Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial
| Autor: | Stelljes, Matthias, Advani, Anjali S, DeAngelo, Daniel J, Wang, Tao, Neuhof, Alexander, Vandendries, Erik, Kantarjian, Hagop, Jabbour, Elias |
|---|---|
| Zdroj: | In Clinical Lymphoma, Myeloma and Leukemia September 2022 22(9):e836-e843 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect